336 related articles for article (PubMed ID: 7537123)
1. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
2. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.
Fruehauf S; Schmitt K; Veldwijk MR; Topaly J; Benner A; Zeller WJ; Ho AD; Haas R
Br J Haematol; 1999 Jun; 105(3):786-94. PubMed ID: 10354148
[TBL] [Abstract][Full Text] [Related]
4. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
Prosper F; Stroncek D; Verfaillie CM
Blood; 1996 Sep; 88(6):2033-42. PubMed ID: 8822922
[TBL] [Abstract][Full Text] [Related]
7. Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow.
Prosper F; Vanoverbeke K; Stroncek D; Verfaillie CM
Blood; 1997 Jun; 89(11):3991-7. PubMed ID: 9166837
[TBL] [Abstract][Full Text] [Related]
8. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; Montaño J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
[TBL] [Abstract][Full Text] [Related]
9. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.
To LB; Haylock DN; Dowse T; Simmons PJ; Trimboli S; Ashman LK; Juttner CA
Blood; 1994 Nov; 84(9):2930-9. PubMed ID: 7524760
[TBL] [Abstract][Full Text] [Related]
11. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
[TBL] [Abstract][Full Text] [Related]
12. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
13. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
[TBL] [Abstract][Full Text] [Related]
15. Primitive hematopoietic progenitor cells are present in peripheral blood autografts.
Tong J; Gianni AM; Siena S; Srour EF; Bregni M; Hoffman R
Blood Cells; 1994; 20(2-3):351-62; discussion 362-3. PubMed ID: 7538339
[TBL] [Abstract][Full Text] [Related]
16. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
[TBL] [Abstract][Full Text] [Related]
18. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
